(Q24248643)

title

Acetyl-L-carnitine for dementia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

14 May 2020

0 references

S Hudson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

14 May 2020

N Tabet

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 May 2020

language of work or name

English

0 references

publication date

22 April 2003

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

14 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

14 May 2020

page(s)

CD003158

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

A 1-year controlled trial of acetyl-L-carnitine in early-onset AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Acetyl-l-Carnitine: A Drug Able to Slow the Progress of Alzheimer's Disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Neuroprotective activity of acetyl-L-carnitine: studies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Amitriptyline and clomipramine activate Gi-protein signaling pathway in the induction of analgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

The prevalence of dementia: a quantitative integration of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression

21 January 2018

1 reference

12 December 2020

Effects of L-acetylcarnitine on mental deterioration in the aged: initial results

1 reference

12 December 2020

Mental impairment in aging: selection of patients, methods of evaluation and therapeutic possibilities of acetyl-L-carnitine.

1 reference

12 December 2020

L-acetylcarnitine treatment of mental decline in the elderly

1 reference

12 December 2020

An example of a clinical trial in patients with Alzheimer's disease: some methodological issues.

1 reference

12 December 2020

A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease

1 reference

12 December 2020

[Methodology of a clinical controlled study of L-acetylcarnitine]

1 reference

12 December 2020

Methodology of a controlled clinical study for cerebral aging evaluation

1 reference

12 December 2020

Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial

1 reference

12 December 2020

Delaying the mitochondrial decay of aging with acetylcarnitine

1 reference

12 December 2020

Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia.

1 reference

12 December 2020

Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome

1 reference

12 December 2020

[A controlled clinical study on the efficacy of L-acetylcarnitine in the treatment of mild-to-moderate mental deterioration in the aged. Conclusions]

1 reference

12 December 2020

Acetyl-L-carnitine in the treatment of mildly demented elderly patients

1 reference

12 December 2020

Neuropsychological changes in demented patients treated with acetyl-L-carnitine.

1 reference

12 December 2020

Acetyl-Carnitine and Alzheimer's Disease

1 reference

12 December 2020

Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency.

1 reference

12 December 2020

The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results

1 reference

12 December 2020

Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach.

1 reference

12 December 2020

L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia

1 reference

12 December 2020

Efficacy and Clinical Relevance of Cognition Enhancers

1 reference

12 December 2020

1 reference

12 December 2020

Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain.

1 reference

12 December 2020

Teaching tape for the motor section of the unified Parkinson's disease rating scale

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003158

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD003158

2 references

Consolidated OpenCitations Corpus – April 2017

1501232

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

14 May 2020

1501232

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6991156&resulttype=core&format=json

14 May 2020

PubMed publication ID

12804452

2 references

Consolidated OpenCitations Corpus – April 2017

1501232